TY - JOUR
T1 - Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer
T2 - An Alternative to Systematic Transfer
AU - Honoré, Charles
AU - Mir, Olivier
AU - Geraud, Arthur
AU - Drovetti, Gianmaria
AU - Garcia, Gabriel C.T.E.
AU - Gustin, Pierre
AU - Colomba, Emeline
AU - Pilorge, Sylvain
AU - Matias, Margarida
AU - Majer, Michael
AU - Balleyguier, Corinne
AU - Azoulay, Mikael
AU - Besse, Benjamin
AU - Herve, Robert
AU - Vial, Gregory
AU - Ducreux, Michel
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - PURPOSE:To report our experience of intercontinental multidisciplinary oncology videoconferencing between the French mainland and South Pacific to discuss rare and/or complex cancer cases.METHODS:On the first and third Friday of each month, all participants connected between 6:30 am and 8:00 am GMT to discuss using a web conference service.RESULTS:Between November 2019 and April 2020, 99 cases concerning 78 patients were discussed. Oncology subspecialties required were sarcoma (n = 36), digestive (n = 29), dermatology (n = 5), gynecology (n = 5), breast (n = 5), urology (n = 5), hematology (n = 5), ENT (n = 3), thoracic (n = 3), thyroid (n = 2), and pediatric (n = 1). Median patient age was 58 years, 41 were female (53%), 37 were male (47%), and 43 had a metastatic disease (55%). Following discussion, 16 patients (21%) were transferred to the French mainland. Reasons for transfer were requirement for complex surgery (n = 11) and need for specialized diagnostic biopsy (n = 5). Fifty-six patients were treated locally, with systemic chemotherapy (n = 36), surveillance (n = 8), surgery (n = 8), radiotherapy (n = 3), or endoscopy (n = 1). Direct benefits for patients treated in their local facility included strategy changes (surveillance or surgery contraindication, n = 9), targeted therapy decision (n = 14), immunotherapy decision (n = 9), and diagnostic or metastatic status corrections (n = 4). Six patients are still awaiting decision.CONCLUSION:Using real-Time intercontinental multidisciplinary oncology videoconferencing to discuss complex or rare cancer cases is reliable and effective for decision making. This concept helped to limit to 21% the need for transfers to the mainland.
AB - PURPOSE:To report our experience of intercontinental multidisciplinary oncology videoconferencing between the French mainland and South Pacific to discuss rare and/or complex cancer cases.METHODS:On the first and third Friday of each month, all participants connected between 6:30 am and 8:00 am GMT to discuss using a web conference service.RESULTS:Between November 2019 and April 2020, 99 cases concerning 78 patients were discussed. Oncology subspecialties required were sarcoma (n = 36), digestive (n = 29), dermatology (n = 5), gynecology (n = 5), breast (n = 5), urology (n = 5), hematology (n = 5), ENT (n = 3), thoracic (n = 3), thyroid (n = 2), and pediatric (n = 1). Median patient age was 58 years, 41 were female (53%), 37 were male (47%), and 43 had a metastatic disease (55%). Following discussion, 16 patients (21%) were transferred to the French mainland. Reasons for transfer were requirement for complex surgery (n = 11) and need for specialized diagnostic biopsy (n = 5). Fifty-six patients were treated locally, with systemic chemotherapy (n = 36), surveillance (n = 8), surgery (n = 8), radiotherapy (n = 3), or endoscopy (n = 1). Direct benefits for patients treated in their local facility included strategy changes (surveillance or surgery contraindication, n = 9), targeted therapy decision (n = 14), immunotherapy decision (n = 9), and diagnostic or metastatic status corrections (n = 4). Six patients are still awaiting decision.CONCLUSION:Using real-Time intercontinental multidisciplinary oncology videoconferencing to discuss complex or rare cancer cases is reliable and effective for decision making. This concept helped to limit to 21% the need for transfers to the mainland.
UR - http://www.scopus.com/inward/record.url?scp=85117541733&partnerID=8YFLogxK
U2 - 10.1200/OP.20.00525
DO - 10.1200/OP.20.00525
M3 - Article
C2 - 33621118
AN - SCOPUS:85117541733
SN - 2688-1527
VL - 17
SP - E1311-E1317
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 9
ER -